CJC-1295
updated
The human CJC-1295 studies tested the DAC form that covalently binds albumin and lasts for days. “CJC-1295 no DAC” is the market name for Modified GRF 1-29, a different molecule that does not inherit those pharmacokinetic results.
long-acting GHRH analogue
- DAC form studied in healthy adults
- Estimated half-life 5.8 to 8.1 days in the phase 1 report
- No-DAC products are Modified GRF 1-29, not the studied long-acting conjugate
- No FDA-approved CJC-1295 product
Which CJC-1295 did the human studies test?
They tested CJC-1295 with DAC, the albumin-binding form. Products called “CJC-1295 no DAC” are usually Modified GRF 1-29 and should be treated as a separate short-acting GHRH analogue.
| Label | Molecule | Can use the published 5.8 to 8.1 day half-life? |
|---|---|---|
| CJC-1295 with DAC | Albumin-reactive GHRH analogue | Yes, under the phase 1 study conditions |
| CJC-1295 no DAC | Market shorthand for Modified GRF 1-29 | No |
The DAC group reacts with circulating albumin. Removing it changes the molecule, so the published multi-day pharmacokinetics no longer apply.
Discovery study · DAC albumin conjugation
Biochemical and animal study
Jetté L et al. Endocrinology, 2005.
The development paper identified CJC-1295 as a GHRH(1-29) analogue carrying a reactive drug-affinity-complex group that forms a covalent bond with albumin after administration. That albumin conjugation is the basis of the long exposure studied later.
- Participants / model
- Biochemical systems and rats
- Treatment
- Albumin-reactive GHRH analogues
- Study design
- Molecular characterization and animal pharmacology
This identity does not describe Modified GRF 1-29 sold as “no DAC.”
Read the original sourceNo-DAC aliases · zero direct PubMed hits
Literature and registry record set
PubMed and ClinicalTrials.gov records.
PubMed contained no human-indexed record under CJC-1295 no DAC, Modified GRF 1-29, or Mod GRF 1-29. ClinicalTrials.gov records under those aliases concerned unrelated GnRH interventions. Human results for the DAC molecule therefore cannot be assigned to the no-DAC market name.
- Study design
- Exact-alias literature and registry coverage with intervention identity classification
What did CJC-1295 do in people?
In healthy adults, the DAC molecule produced sustained increases in GH and IGF-1. The studies measured hormones, pharmacokinetics, and short-term tolerability; they did not show better sleep, injury recovery, fat loss, or muscle gain.
After one dose in the ascending-dose study, mean GH rose for at least six days and mean IGF-1 for nine to eleven days. In the intensive-sampling study, GH pulses remained present, but higher trough GH accounted for much of the increased overall secretion.
What happened to GH pulses and baseline levels?
GH pulse frequency and amplitude remained unchanged, while trough and mean GH rose and IGF-1 stayed elevated for days.
DAC study · preserved pulses, higher trough
Human physiology study
Ionescu M, Frohman LA. Journal of Clinical Endocrinology and Metabolism, 2006.
Healthy men were sampled every 20 minutes overnight before and one week after CJC-1295. Pulse frequency and magnitude were unchanged, while trough GH, mean GH, and IGF-1 increased. The result describes endocrine physiology after the DAC molecule, not recovery or body-composition outcomes.
- Participants / model
- Healthy men aged 20 to 40
- Treatment
- One subcutaneous dose of 60 or 90 micrograms per kilogram CJC-1295
- Follow-up
- Baseline and one-week assessment
- Study design
- Before-and-after intensive hormone sampling study
Are the results evidence for no-DAC CJC?
No. The measured persistence depends on DAC-mediated albumin binding. PubMed and ClinicalTrials.gov listed no direct human study under the no-DAC market aliases.
No-DAC aliases · zero direct PubMed hits
Literature and registry record set
PubMed and ClinicalTrials.gov records.
PubMed contained no human-indexed record under CJC-1295 no DAC, Modified GRF 1-29, or Mod GRF 1-29. ClinicalTrials.gov records under those aliases concerned unrelated GnRH interventions. Human results for the DAC molecule therefore cannot be assigned to the no-DAC market name.
- Study design
- Exact-alias literature and registry coverage with intervention identity classification
CJC-1295 DAC · phase 1 hormone and PK study
Two randomized phase 1 trials
Teichman SL et al. Journal of Clinical Endocrinology and Metabolism, 2006.
In two double-blind ascending-dose studies lasting 28 and 49 days, subcutaneous CJC-1295 produced dose-related increases in mean GH for at least six days and IGF-1 for nine to eleven days after one injection. The estimated half-life was 5.8 to 8.1 days. No serious adverse reactions were reported in this small, short study.
- Participants / model
- Healthy adults aged 21 to 61
- Treatment
- Single ascending doses, followed by two or three weekly or biweekly subcutaneous doses in the repeat-dose study
- Follow-up
- 28 and 49 days
- Study design
- Randomized, placebo-controlled, double-blind phase 1 studies
- Funding
- ConjuChem
Hormone changes and short-term tolerability are not clinical outcome benefits.
Read the original sourceDAC study · preserved pulses, higher trough
Human physiology study
Ionescu M, Frohman LA. Journal of Clinical Endocrinology and Metabolism, 2006.
Healthy men were sampled every 20 minutes overnight before and one week after CJC-1295. Pulse frequency and magnitude were unchanged, while trough GH, mean GH, and IGF-1 increased. The result describes endocrine physiology after the DAC molecule, not recovery or body-composition outcomes.
- Participants / model
- Healthy men aged 20 to 40
- Treatment
- One subcutaneous dose of 60 or 90 micrograms per kilogram CJC-1295
- Follow-up
- Baseline and one-week assessment
- Study design
- Before-and-after intensive hormone sampling study
How does the DAC form work?
CJC-1295 activates the pituitary GHRH receptor and uses covalent albumin binding to prolong exposure. Human phase 1 studies measured higher GH and IGF-1, not sleep, recovery, fat loss, or muscle gain.
The molecule does not supply growth hormone directly. It stimulates a functioning pituitary. That means response can depend on pituitary reserve, age, disease, and other endocrine conditions.
Can a hormone increase be treated as a clinical benefit?
No. GH and IGF-1 are biomarkers and biological mediators. A study must measure the specific patient outcome before claiming better recovery, body composition, sleep, or function.
CJC-1295 DAC · phase 1 hormone and PK study
Two randomized phase 1 trials
Teichman SL et al. Journal of Clinical Endocrinology and Metabolism, 2006.
In two double-blind ascending-dose studies lasting 28 and 49 days, subcutaneous CJC-1295 produced dose-related increases in mean GH for at least six days and IGF-1 for nine to eleven days after one injection. The estimated half-life was 5.8 to 8.1 days. No serious adverse reactions were reported in this small, short study.
- Participants / model
- Healthy adults aged 21 to 61
- Treatment
- Single ascending doses, followed by two or three weekly or biweekly subcutaneous doses in the repeat-dose study
- Follow-up
- 28 and 49 days
- Study design
- Randomized, placebo-controlled, double-blind phase 1 studies
- Funding
- ConjuChem
Hormone changes and short-term tolerability are not clinical outcome benefits.
Read the original sourceDiscovery study · DAC albumin conjugation
Biochemical and animal study
Jetté L et al. Endocrinology, 2005.
The development paper identified CJC-1295 as a GHRH(1-29) analogue carrying a reactive drug-affinity-complex group that forms a covalent bond with albumin after administration. That albumin conjugation is the basis of the long exposure studied later.
- Participants / model
- Biochemical systems and rats
- Treatment
- Albumin-reactive GHRH analogues
- Study design
- Molecular characterization and animal pharmacology
This identity does not describe Modified GRF 1-29 sold as “no DAC.”
Read the original sourceCJC-1295 DAC · phase 1 hormone and PK study
Two randomized phase 1 trials
Teichman SL et al. Journal of Clinical Endocrinology and Metabolism, 2006.
In two double-blind ascending-dose studies lasting 28 and 49 days, subcutaneous CJC-1295 produced dose-related increases in mean GH for at least six days and IGF-1 for nine to eleven days after one injection. The estimated half-life was 5.8 to 8.1 days. No serious adverse reactions were reported in this small, short study.
- Participants / model
- Healthy adults aged 21 to 61
- Treatment
- Single ascending doses, followed by two or three weekly or biweekly subcutaneous doses in the repeat-dose study
- Follow-up
- 28 and 49 days
- Study design
- Randomized, placebo-controlled, double-blind phase 1 studies
- Funding
- ConjuChem
Hormone changes and short-term tolerability are not clinical outcome benefits.
Read the original sourceWhat safety concerns are known?
The phase 1 program reported no serious adverse reactions, but FDA identifies increased heart rate and a systemic vasodilatory reaction among serious events associated with CJC-1295. Long-term safety and no-DAC safety remain unresolved.
- Acute exposure: flushing, cardiovascular reactions, headache, and injection reactions are plausible concerns in this drug class; FDA specifically cites increased heart rate and systemic vasodilation for CJC-1295.
- Sustained IGF-1: the human studies showed prolonged elevation but were not designed to establish long-term metabolic, cardiovascular, or proliferative safety.
- Product identity: a vial labeled CJC-1295 may contain DAC, no-DAC, a salt, an impurity, or a different concentration.
CJC-1295 DAC · phase 1 hormone and PK study
Two randomized phase 1 trials
Teichman SL et al. Journal of Clinical Endocrinology and Metabolism, 2006.
In two double-blind ascending-dose studies lasting 28 and 49 days, subcutaneous CJC-1295 produced dose-related increases in mean GH for at least six days and IGF-1 for nine to eleven days after one injection. The estimated half-life was 5.8 to 8.1 days. No serious adverse reactions were reported in this small, short study.
- Participants / model
- Healthy adults aged 21 to 61
- Treatment
- Single ascending doses, followed by two or three weekly or biweekly subcutaneous doses in the repeat-dose study
- Follow-up
- 28 and 49 days
- Study design
- Randomized, placebo-controlled, double-blind phase 1 studies
- Funding
- ConjuChem
Hormone changes and short-term tolerability are not clinical outcome benefits.
Read the original sourceFDA safety page · heart-rate and vasodilatory events
FDA safety communication
US Food and Drug Administration.
FDA cites limited clinical data, peptide impurity and immunogenicity concerns, and serious adverse events associated with CJC-1295 including increased heart rate and a systemic vasodilatory reaction.
- Study design
- Agency safety summary
The FDA source does not resolve DAC versus no-DAC for every reported product.
Read the original sourceIs CJC-1295 approved or allowed in tested sport?
FDA approval records contain no CJC-1295 product. FDA continues to list compounding safety concerns, and GHRH analogues are prohibited for athletes covered by WADA rules.
The old ConjuChem development program and published phase 1 data do not create a current approval, label, or validated community regimen.
FDA safety page · heart-rate and vasodilatory events
FDA safety communication
US Food and Drug Administration.
FDA cites limited clinical data, peptide impurity and immunogenicity concerns, and serious adverse events associated with CJC-1295 including increased heart rate and a systemic vasodilatory reaction.
- Study design
- Agency safety summary
The FDA source does not resolve DAC versus no-DAC for every reported product.
Read the original sourceWADA 2026 · GHRH analogues
Sports rule
World Anti-Doping Agency, effective 1 January 2026.
Growth-hormone-releasing factors and their analogues are prohibited under S2 for athletes covered by the Code.
- Study design
- Binding sport rule for covered athletes
Studies and sources
CJC-1295 DAC · phase 1 hormone and PK study
Two randomized phase 1 trials
Teichman SL et al. Journal of Clinical Endocrinology and Metabolism, 2006.
In two double-blind ascending-dose studies lasting 28 and 49 days, subcutaneous CJC-1295 produced dose-related increases in mean GH for at least six days and IGF-1 for nine to eleven days after one injection. The estimated half-life was 5.8 to 8.1 days. No serious adverse reactions were reported in this small, short study.
- Participants / model
- Healthy adults aged 21 to 61
- Treatment
- Single ascending doses, followed by two or three weekly or biweekly subcutaneous doses in the repeat-dose study
- Follow-up
- 28 and 49 days
- Study design
- Randomized, placebo-controlled, double-blind phase 1 studies
- Funding
- ConjuChem
Hormone changes and short-term tolerability are not clinical outcome benefits.
Read the original sourceDAC study · preserved pulses, higher trough
Human physiology study
Ionescu M, Frohman LA. Journal of Clinical Endocrinology and Metabolism, 2006.
Healthy men were sampled every 20 minutes overnight before and one week after CJC-1295. Pulse frequency and magnitude were unchanged, while trough GH, mean GH, and IGF-1 increased. The result describes endocrine physiology after the DAC molecule, not recovery or body-composition outcomes.
- Participants / model
- Healthy men aged 20 to 40
- Treatment
- One subcutaneous dose of 60 or 90 micrograms per kilogram CJC-1295
- Follow-up
- Baseline and one-week assessment
- Study design
- Before-and-after intensive hormone sampling study
Discovery study · DAC albumin conjugation
Biochemical and animal study
Jetté L et al. Endocrinology, 2005.
The development paper identified CJC-1295 as a GHRH(1-29) analogue carrying a reactive drug-affinity-complex group that forms a covalent bond with albumin after administration. That albumin conjugation is the basis of the long exposure studied later.
- Participants / model
- Biochemical systems and rats
- Treatment
- Albumin-reactive GHRH analogues
- Study design
- Molecular characterization and animal pharmacology
This identity does not describe Modified GRF 1-29 sold as “no DAC.”
Read the original sourceNo-DAC aliases · zero direct PubMed hits
Literature and registry record set
PubMed and ClinicalTrials.gov records.
PubMed contained no human-indexed record under CJC-1295 no DAC, Modified GRF 1-29, or Mod GRF 1-29. ClinicalTrials.gov records under those aliases concerned unrelated GnRH interventions. Human results for the DAC molecule therefore cannot be assigned to the no-DAC market name.
- Study design
- Exact-alias literature and registry coverage with intervention identity classification
FDA safety page · heart-rate and vasodilatory events
FDA safety communication
US Food and Drug Administration.
FDA cites limited clinical data, peptide impurity and immunogenicity concerns, and serious adverse events associated with CJC-1295 including increased heart rate and a systemic vasodilatory reaction.
- Study design
- Agency safety summary
The FDA source does not resolve DAC versus no-DAC for every reported product.
Read the original sourceWADA 2026 · GHRH analogues
Sports rule
World Anti-Doping Agency, effective 1 January 2026.
Growth-hormone-releasing factors and their analogues are prohibited under S2 for athletes covered by the Code.
- Study design
- Binding sport rule for covered athletes
Why is CJC-1295 in A tier?
The A grade reflects direct human pharmacokinetic and hormone data for CJC-1295 with DAC. No-DAC products are different molecules, and the studies did not establish benefits for sleep, recovery, fat loss, or muscle gain.
read CJC-1295 in the reptides guide, chapter 07: 8 pages, free to read.